New insights into the interplay between MALAT1 and miRNA-155 to unravel potential diagnostic and prognostic biomarkers of Behçet’s disease
Clinical Rheumatology · 2025
DOI: 10.1007/s10067-024-07291-x ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Rheumatology, 2025. Verfasst von Noha H Sayed und 4 weiteren Autor:innen. Beteiligte Einrichtung: Biochemistry Department, Faculty of Pharmacy, Cairo University, Cairo, 11562, Egypt. Hauptthemen laut MEDLINE: Behcet Syndrome, MicroRNAs, RNA, Long Noncoding. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cairo University.
Abstract (Originalsprache)
The current study was deployed to evaluate the role of metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) and miR-155, along with the inflammatory markers, TNFα and IL-6, and the adhesion molecule, cluster of differentiation 106 (CD106), in Behçet’s disease (BD) pathogenesis. The study also assessed MALAT1/miR-155 as promising diagnostic and prognostic biomarkers for BD. The current retrospective case–control study included 74 Egyptian BD patients and 50 age and sex-matched controls. Blood samples were collected, and then, serum samples were separated for further biochemical and molecular investigations. The gene expression of MALAT1 and miR-155 was measured using qRT-PCR, whereas the levels of TNFα, IL-6, and CD106 were estimated using ELISA technique. MALAT1 was significantly downregulated, whereas miR-155 was upregulated among BD patients, compared with control subjects. Levels of TNFα, IL-6, and CD106 were elevated in BD patients. Further downregulation in MALAT1 together with upregulation of miR-155 was observed in active BD patients, relative to the inactive group. Receiver-operating-characteristic analysis revealed that MALAT1 and miR-155 could discriminate BD patients from controls, on the one hand, and active from inactive BD patients, on the other hand. MALAT1 was negatively correlated with TNFα, IL-6, and CD106, while miR-155 was positively correlated with them. Logistic regression analyses demonstrated miR-155 as a significant independent predictor of BD susceptibility, and MALAT1 as an independent negative predictor of BD activity. For the first time, the current research enlightens the role of MALAT1 and miR-155 in BD pathogenesis via impacting IL-6/TNF-α/CD-106 signaling. As well, MALAT1 and miR-155 could be regarded as novel non-invasive biomarkers that may improve BD diagnosis and prognosis. Key Points •MALAT1/miR-155 exerts potential role in Behçet’s disease. •MALAT1/miR-155 are promising biomarkers for Behçet’s disease. •MALAT1/miR-155 targets IL-6/TNF-α/CD-106 signaling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biochemistry Department, Faculty of Pharmacy, Cairo University, Cairo, 11562, Egypt.
- Medical Biochemistry and Molecular Biology Department, Faculty of Medicine, Cairo University, Cairo, 11562, Egypt.
- Biochemistry Department, Faculty of Pharmacy, Cairo University, Cairo, 11562, Egypt. mei.abdelmawla@pharma.cu.edu.eg.
- Andrology, Sexology and STI's Department, Faculty of Medicine, Cairo University, Cairo, 11562, Egypt.
Förderung
- Cairo University
Zitieren
APA
Sayed, N. H., Shaker, O. G., Abd-Elmawla, M. A., Gamal, A., & Fathy, N. (2025). New insights into the interplay between MALAT1 and miRNA-155 to unravel potential diagnostic and prognostic biomarkers of Behçet’s disease. Clinical Rheumatology. https://doi.org/10.1007/s10067-024-07291-x
Vancouver
Sayed NH, Shaker OG, Abd-Elmawla MA, Gamal A, Fathy N. New insights into the interplay between MALAT1 and miRNA-155 to unravel potential diagnostic and prognostic biomarkers of Behçet’s disease. Clinical Rheumatology. 2025. doi:10.1007/s10067-024-07291-x
BibTeX
@article{Sayed2025,
author = {Sayed, Noha H and Shaker, Olfat G and Abd-Elmawla, Mai A and Gamal, Ahmed and Fathy, Nevine},
title = {New insights into the interplay between MALAT1 and miRNA-155 to unravel potential diagnostic and prognostic biomarkers of Behçet’s disease},
journal = {Clinical Rheumatology},
year = {2025},
doi = {10.1007/s10067-024-07291-x}
}
EUVIMED